The mission of the Centre for Systems Medicine is to provide a translational research centre which identifies genes, proteins and metabolites implicated in human disease. The Centre utilizes bioinformatics, systems biology and machine learning approaches to develop new prognostic tools for the treatment of cancer, neurological and metabolic disorders and  to develop more targeted therapies for patients.

What is Systems Medicine?

For a short and understandable explanation please watch the animation provided by ZonMw

CSM Director, Prof. Jochen Prehn provides and overview of the research activities at the Centre for Systems Medicine

For additional Videos, click on each investigator’s page to learn about what projects they are leading at the CSM                                             

CSM Director: Prof. Jochen Prehn

 

 CSM Scientific Liaison Officer: Dr. Helena Bonner  

                   

Recent Highlights:

Small RNA sequencing identifies serum tDR-1:34-Gly-GCC tiRNA levels as a biomarker for survival in amyotrophic lateral sclerosis (2026)

Neuronal vulnerability in Parkinson’s disease: insights from murine α-synuclein pathology models (2026)

In vitro identification of kainic acid-induced, concentration-dependent responses in human cortical neuronal networks ( 2026)

A pipeline of machine learning-driven multi-modal data fusion methods for prognostic risk analysis in bevacizumab-treated metastatic colorectal cancer. (2026)

Biofluid-specific variations in circulating 5′ transfer RNA fragments during ictal and interictal states in experimental temporal lobe epilepsy. (2026)

A neural network model delivers a highly prognostic protein signature in cancer stem cells that identifies relapse in stage III colorectal cancer patients (2026)

Temporal Dynamics of tsRNA Regulation Mark an Abrupt Transition After Epileptogenesis (2025)

Protective role of Angiogenin in muscle regeneration in amyotrophic lateral sclerosis: Diagnostic and therapeutic implications.(2025)

Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy (2023)

Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers (2023)

Multiplexed Immunofluorescence Imaging Reveals an Immune Rich Tumor Microenvironment in Mucinous Rectal Cancer Characterized by Increased Lymphocyte Infiltration and Enhanced PD-1 Expression (2023)

An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution (2022)

Mechanisms and mathematical modelling of ROS production by the mitochondrial electron transport chain (2022)

Patients with mesenchymal tumours and high Fusobacteriales prevalence have worse prognosis in colorectal cancer (CRC) (2022)

Angiogenin and tRNA fragments in Parkinson’s disease and neurodegeneration.(2020)

System-based approaches as prognostic tools for glioblastoma (2019)

An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution (2022)

Heterogeneous responses to low level death receptor activation are explained by random molecular assembly of the Caspase-8 activation platform (2019)

Systems biology identifies preserved integrity but impaired metabolism of mitochondria due to a glycolytic defect in Alzheimer’s disease neurons.  Aging Cell. 2019 Jun

A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic.  JCO Clin Cancer Inform. 2019 

Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. Nat Commun. 2018 Oct  

Click here for a list of all the Publications